The Value Research Of MRU、MRS In Combination With PSA In The Differentiation Of Prostate Carcinoma And Benign Prostate Hyperplasia

Research the value of MRI, MRS joint Serum prostate-specific antigen (PSA)n the identification of prostate cancer (PCa) and benign prostatic hyperplasia(BPH).Materials and Methods: Collecting the materials in our hospital from October2011to December2012ranging biopsy, surgery to follow-up who wereconfirmed48cases of patients prostate, including prostate cancer (22cases),benign prostatic hyperplasia (26cases). There are30patients (PCa16cases, BPH14cases) using Line MRS scanning. Prostate morphology assessment onconventional MRI images, lesion location, size, signal characteristics, as well asthe scope of violations; observing citrate (Cit), choline composite material (Cho),creatine (Cr) peaks and chemical shifts using MRS diagnosing and judging PCaand BPH through measuring the rate of Cho+Cr)/Cit.48patients weretested on PSA and got data, then confirmed by pathological results, gaining thecheck of MRI, MRS, PSA and the three combined for the sensitivity, specificity,and accuracy of the identification of PCa and BPH.Results:16cases out of22cases of PCa patients resulted from the peripheralzone (PZ),2cases in the central belt (CG),4cases involving the peripheral zoneand the central belt at the same time; There are nodular or plaque piecelike lowsignal on T2WI, of which14cases are unilateral focal lesions, eight cases arebilateral diffuse multiple lesions;24cases originated in the central zone and thetransitional zone of26patients with BPH patients, only two cases originated in the peripheral zone. InT2WI image the volume of prostate transitional zone andthe central belt increases, presenting the abnormal signal intensity in it andnodular hyperplasia stretched forward and bottom of the bladder. Among them10cases showed a level of nodular mixed signal16patients showed diffuse increasein size, uniforming nodular high signal (10cases), low signal (6cases). The MRSimage shows:16cases of PCa patients citrate concentration (Cit) decreasedsignificantly or even disappeared.Cho concentrations increased significantly,measured (Cho+Cr)/Cit value is higher significantly, the two peaks is invertedobviously; while4cases out of14cases in patients14with BPH. There is noobvious changes in Cit peak and Cho peak, in10cases Cit peak slightlydecreased, but no significant changes in Cho peak,measured (Cho+Cr)/Citvalues do not change significantly.16cases of PCa (Cho+Cr)/Cit value of1.98±0.95,14patients with BPH (Cho+Cr)/Cit value of0.60±0.28, the differencebetween the two groups is statistically significant (t=3.256, p <0.001). Received22cases of PCa PSA range is3.42~3126ng/ml, among them, there are20cases>10ng/ml, while2cases <10ng/ml;26patients with BPH,their PSA ranges from1.18to67.56ng/ml, of which,6cases are>10ng of/ml20cases were <10ng/ml.The identification based on PSA is high sensitivity of PCa and BPH (93.1%),while the specificity and accuracy are less higher (65.7%,79.1%). The diagnosedresults of MRI, MRS, the PSA joint are96.4%,84.1%,90.0%.Conclusions: MRI can clearly provide the size of the lesion, location, signalcharacteristics, as well as shifts surrounding it. MRS can provide the biochemical metabolic information of prostate early that is non-invasive. It can provide astrong basis for its early diagnosis, and efficacy testing. Prostate specific antigenPSA is widely regarded as the most valuable tumor marker for prostate cancer,has been widely used in prostate benign and malignant disease diagnosis,differential diagnosis, and provide important indicator for prostate cancer patientswho were followed up. MRI, MRS and PSA inspection methods combined havegreatly improve the sensitivity, specificity and accuracy of diagnosis of prostatecancer, providing significant value for identifying PCa and BPH.